Journal of Contemporary Medicine (Jun 2020)
The Pediatric Case of a Recently Defined Syndrome: Shrunken Pore Syndrome
Abstract
INTRODUCTION: Creatinine was started to be used as a marker of glomerular filtration rate (GFR) in 1920’s. Later in the 1990s, cystatin C was shown to be superior to creatinine in assessing GFR. In some patients, glomerular filtration of cystatin C was found to be low compared to creatinine, and it was hypothesized that glomerular pores may have been shrunken in these patients. For the group of patients having a cystatin C based estimation of GFR (eGFR cystatin C) to creatinine-based estimation of GFR (eGFR creatinine) ratio of ≤60%, the pathophysiological classification is defined as Shrunken Pore Syndrome. CASE: A 16-month-old female patient was admitted to Ege University Pediatric nephrology clinic with the diagnosis of neurogenic bladder secondary to meningomyelocele. She had a history of antenatal meningomyelocele, and hydrocephalus diagnosed as Arnold Chiari type 2. On postnatal day 1, she had undergone meningomyelocele sac excision and ventriculoperitoneal shunt operation. There was no history of pyelonephritis. Systemic examination revealed a dysmorphic facial appearance, operation scar on her back and syndactyly of the toes, and paraplegia on neurological examination. In laboratory examination; urea: 24 mg/dL, creatinine: 0.3 mg/dL, parathormone: 47 ng/mL, cystatin C: 1.4 mg/L (RR: 0.53-0.95), blood β2 microglobulin: 2716 ng/mL. Patient’s eGFRcystatin C: 107 ml/min/1.73m2 and eGFRcreatinine: 188 ml/min/1.73m2. Shrunken Pore Syndrome was considered due to the difference between the patient's eGFRcystatin C value and eGFRcreatinine value. CONCLUSION: Shrunken Pore Syndrome has no known treatment; however, it is important to diagnose these patients because of accompanying risks such as increased cardiac mortality. With the usage of cystatin C as a marker of GFR, possible mortality risks can be predictable and preventive measures can be taken early on.
